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Autocatalytic ampliﬁcation of Alzheimer-
associated Aβ42 peptide aggregation in human
cerebrospinal ﬂuid
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Alzheimer’s disease is linked to amyloid β (Aβ) peptide aggregation in the brain, and a
detailed understanding of the molecular mechanism of Aβ aggregation may lead to improved
diagnostics and therapeutics. While previous studies have been performed in pure buffer, we
approach the mechanism in vivo using cerebrospinal ﬂuid (CSF). We investigated the
aggregation mechanism of Aβ42 in human CSF through kinetic experiments at several Aβ42
monomer concentrations (0.8–10 µM). The data were subjected to global kinetic analysis and
found consistent with an aggregation mechanism involving secondary nucleation of mono-
mers on the ﬁbril surface. A mechanism only including primary nucleation was ruled out. We
ﬁnd that the aggregation process is composed of the same microscopic steps in CSF as in
pure buffer, but the rate constant of secondary nucleation is decreased. Most importantly, the
autocatalytic ampliﬁcation of aggregate number through catalysis on the ﬁbril surface is
prevalent also in CSF.
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A lzheimer’s disease (AD) is a devastating neurodegenera-tive disease, which affects a large and increasing numberof individuals world-wide1,2. The sequence of events
leading to the initiation and propagation of this neurodegenera-
tive disease is still largely unknown; however, in addition to aging
and the major genetic risk gene apolipoprotein E (APOE), pos-
sible mechanisms including inﬂammation3, altered endosomal
sorting4,5, and tau spreading6 are gaining increasing awareness.
There is ample evidence linking the self-assembly of the amyloid
β peptide (Aβ) to the disease7,8. According to the amyloid cascade
hypothesis, Aβ self-assembly is followed by truncation, phos-
phorylation and aggregation of tau, and subsequent neuronal
death9–11.
Aβ was discovered in 198412 and its complete amino acid
sequence in plaques was determined in 198513. Several length
variants of this peptide have been found to coexist in body ﬂuids,
including cerebrospinal ﬂuid (CSF) and blood serum14–17.
Typical Aβ42 concentration in CSF are around 250 pM in healthy
humans, with a large variation between individuals. Around 50%
lower average Aβ42 concentration is measured in CSF from AD
patients, which is thought to arise from sequestration of Aβ42
into plaques in the brain18. Evidence for the association between
Aβ and AD largely come from the early onset of AD-type
pathology in individuals with extra dosage due to chromosome 21
trisomy19,20, as well as from familial AD cases with mutations
close to the γ secretase cleavage site of amyloid precursor protein
(APP)21,22 and before the β secretase cleavage site at the N-
terminus of Aβ23, or with Aβ variants that are more aggregation-
prone or follow an altered aggregation pathway24–27.
Self-assembly of Aβ leads to the formation of elongated ﬁbrillar
aggregates of highly ordered structure28,29, whereas smaller
aggregates—oligomers—formed during the process seem to be
responsible for the emergence of neurotoxicity30. Oligomers are
transient species and a range of deﬁnitions has been used in the
literature, including aggregates with lower growth rate than
ﬁbrils, aggregates in a discrete size range, or aggregates that are
toxic, as reviewed31. One route towards future diagnostics and
treatment of AD involves ﬁnding the mechanism of Aβ aggre-
gation in terms of the microscopic steps in the process32 and the
molecular driving forces of each step26,33. Such knowledge can be
used to search for inhibitors of particular steps, most importantly
those steps leading to toxicity34,35.
Recent investigations of highly puriﬁed peptide in buffer have
revealed a mechanism that is compatible both with a large set of
aggregation kinetics data at multiple peptide concentrations and
with experiments using isotope-enrichment to decipher the origin
of oligomeric species32. The result is a double nucleation
mechanism compatible with the aggregation of Aβ4232, Aβ4036 as
well as several point mutations26,27 and variants with N-terminal
extensions37. Primary nucleation in solution is accompanied with
a very high energy barrier compared to elongation of existing
aggregates38. Once ﬁbrillar aggregates have formed, these present
a catalytic surface for secondary nucleation of monomers. This
secondary nucleation process is associated with a much lower
energy barrier than primary nucleation38 and leads to an auto-
catalytic process with rapid multiplication of the number of
aggregates. Although secondary nucleation of Aβ monomers on
ﬁbril surface was not discovered until 2013, this type of process,
leading to autocatalytic ampliﬁcation of aggregate mass, has been
known in crystallization and other self-assembly processes for
more than a century, as reviewed39–42.
Aβ aggregation in vivo occurs in complex ﬂuids containing
many thousands types of proteins in addition to phospholipids,
metabolites, salts, and other components. At least two approaches
are possible to understand any changes in the mechanism com-
pared to the pure buffer system. In a bottom-up approach,
components from relevant ﬂuids are added one at a time and the
effect on the Aβ aggregation mechanism is quantiﬁed to ﬁnd the
effects on each of the underlying microscopic steps. This
approach is the fastest route towards a detailed physico-chemical
understanding of the effects from each component and was
recently used to understand the effects of ionic strength33,43 and
pH26. In a top-down approach, as in the current work, Aβ
aggregation is studied in a full body ﬂuid. This approach is the
fastest route towards the aggregation mechanism in a complex
environment, but does not provide a clear understanding of the
connection between effects and effectors due to multiple simul-
taneous effects.
In this study, we investigate the aggregation of Aβ42 in the
presence of CSF using the amyloid-binding dye thioﬂavin T
(ThT), which, when used in a ﬂuorescence assay, produces
remarkably reproducible data over a range of peptide con-
centrations in a pure buffer system44. We also use cryo-EM to
conﬁrm that the end stage consists of ﬁbrils very similar to those
seen in pure buffer systems. The kinetic data generated by the
ThT assay remains reproducible and amenable to kinetic analysis
over a wide span of CSF concentrations. Pure monomer, or pure
monomer supplemented with pre-formed seeds, was combined
with CSF at multiple peptide concentrations and a model was
globally ﬁtted to the data as a function of concentration and
time45 to ﬁnd the minimal mechanism compatible with all data.
Our conclusion is that although CSF has a generally retarding
effect on Aβ aggregation, the same mechanism, including a
double step secondary nucleation process, remains dominant in
the presence of CSF.
Results
Validation of automated pipetting by robot. The pipetting
robot used for all dilution series in this work was validated by
dispensing different concentrations of a ﬂuorescent dye solution
and measuring the resulting ﬂuorescent signals. The same con-
centration was dispensed four times within each experiment and
three separate experiments were made. The results show a high
degree of linearity between expected concentration and ﬂuores-
cence intensity and high reproducibility both within and between
the independent experiments (Supplementary Fig. 1).
Aβ42 aggregation kinetics in buffer. Since CSF contains ca. 140
mM NaCl and 1 mM CaCl246, the aggregation kinetics starting
from a range of Aβ42 monomer concentrations, 0.8–10 µM, were
ﬁrst studied in 20mM HEPES/NaOH, 140 mM NaCl, 1 mM
CaCl2, pH 8.0 with 10 µM ThT (due to the addition of calcium,
use of phosphate buffer as in our previous work was not possible).
Four separately mixed replicates of each solution were placed in
separate wells of a 96-well plate (Corning 3881 PEGylated poly-
styrene black plates with half-area wells with clear bottom) and
the ThT ﬂuorescence measured through the bottom of the plate.
The whole experiment was repeated twice. The aggregation
curves from one experiment are shown in Fig. 1a and from
the other in Supplementary Fig. 2. The time at which the ThT
intensity has reached half-way in between the initial baseline and
the ﬁnal plateau values, t1/2, was extracted from each curve and
plotted versus Aβ42 concentration in Fig. 1b, c, and a power
function was ﬁtted to the resulting values
t1=2 ¼ α  cγ ð1Þ
where γ is the scaling exponent, c the Aβ42 concentration, and α a
proportionality constant. We obtain an overall average of γ=
−0.3 for the two experiments shown in Fig. 1a and Supplemen-
tary Fig. 2, while γ=−0.8 was recently found in phosphate buffer
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at similar ionic strength and pH (4 mM sodium phosphate,
0.04 mM EDTA, 150 mM NaCl, pH 8.033).
Effect of CSF concentration. Next, the overall effect of CSF on
Aβ42 aggregation kinetics was investigated at constant Aβ42
concentration as a function of CSF concentration. As several
pools of CSF were used, all datasets with CSF have been marked
with a hexagonal symbol representing the pool used in the
experiment, where L is a pool from Lund and G is a pool from
Gothenburg. Solutions of freshly isolated monomeric recombi-
nant Aβ42 were complemented with buffer, salts, ThT, and CSF
to obtain a series of samples with varying CSF concentration
(0–80%) at constant Aβ42 concentration (3 or 5 µM), and con-
stant concentration of all other components: 10 µM ThT, 20 mM
HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0. Each
experiment was repeated twice with three replicates of each
solution per repeat. Examples of data with 3 µM Aβ42 are shown
in Fig. 2a and the rest of the data in Supplementary Fig. 3. We
ﬁnd an increase in ThT ﬂuorescence with increasing time and
Aβ42 concentrations, comparable to the observations in buffer,
strongly indicating the formation of Aβ42 ﬁbrils in CSF. Com-
pared to buffer data, we ﬁnd a retarding effect of CSF which is
prominent already at low (1%) CSF concentration and levels off
at high CSF concentrations. At 3 and 5 µM Aβ42, we note that all
aggregation proﬁles (ThT signal versus time) at low and high CSF
concentration have a sigmoidal-like appearance with a lag phase,
a growth phase, a ﬁnal plateau, and a relatively symmetric shape
around the midpoint of the growth phase. At intermediate CSF
concentrations (ca. 4–20%), the curves are somewhat asymmetric
and the initiation of the growth phase is more steep than its end
(Supplementary Figs. 3 and 4).
The t1/2 value was extracted from each curve for 3 µM Aβ42 in
Fig. 2a and plotted versus CSF concentration in Fig. 2b. We note
that t1/2 versus CSF concentration follows a hyperbolic trend,
suggesting that the retarding effect is due to one or more
components in CSF interacting with some Aβ42 species along the
aggregation pathway. This CSF concentration-dependent retarda-
tion was found for two other pools of CSF, one yielding a similar
hyperbolic trend (Supplementary Fig. 3b, c)47,48, while for the other
we observed a biphasic effect of t1/2 (Supplementary Fig. 3d, e).
This was used to guide the choice of CSF concentrations for a
further detailed mechanistic study, to represent one concentration
where half maximal effect on t1/2 was observed (15%), one
concentration where ca. 80% of the maximum effect is observed
(32%), and one concentration close to full effect (66%).
The maximum ThT ﬂuorescence intensity between initial
baseline and ﬁnal plateau was evaluated at 3 and 5 µM Aβ42 and
shows a small and non-systematic dependence on the CSF
concentration (Supplementary Figs. 3–5). The exact pattern deviates
between the different trials, as well as the maximum intensity,
which could be due to three different pools of CSF being used in
these experiments. Since nearly all Aβ42 is consumed at the end of
the reaction in the absence of CSF, any increase in ThT intensity
must reﬂect a change in the ThT quantum yield or its afﬁnity to
ﬁbrils rather than an increase in amount of ﬁbrils formed.
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Fig. 1 Aggregation kinetics in buffer. a The ThT ﬂuorescence intensity as a function of time (h) for 0.8–10 µM Aβ42 in buffer. b The calculated t1/2 (h) as a
function of Aβ42 concentration, with a ﬁtted power function as in Eq. (1). The error bars are the standard deviations from the n= 4 repeats per Aβ42
concentration. c Shows the double log representation of (b). The ﬂuorescence data underlying each time trace as well as the t1/2 values and the associated
standard deviations can be found in Supplementary Data 1
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Fig. 2 Aggregation kinetics in constant Aβ42 concentration. a The ThT ﬂuorescence as a function of time for 3 µM Aβ42 in buffer with various
concentrations of CSF (0–80%). The hexagonal ﬁgure represents the CSF pool used. b The t1/2 as estimated from the data in panel (a) as a function of CSF
concentration. The error bars are the standard deviations from the n= 3 repeats per CSF concentration. The ﬂuorescence data underlying each time trace
as well as the t1/2 values and the associated standard deviations can be found in Supplementary Data 2
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Cryo-EM imaging. To further investigate the formation of ﬁbrils
in the presence of CSF, samples of 10 µM Aβ42 in the presence
of 15% and 66% CSF, in 20 mM HEPES/NaOH, 140 mM NaCl,
1 mM CaCl2, 10 µM ThT were monitored using the ThT ﬂuor-
escence assay, collected after reaching the plateau, and imaged
using cryo electron microscopy (cryo-EM; Fig. 3b, c). These
images show that ﬁbrils are clearly formed also in the presence of
CSF, appearing similar to ﬁbrils formed at the same ionic strength
without CSF (Fig. 3a)33, and that they display the hallmark
morphological features of amyloid ﬁbrils, being unbranched and
ribbon-like with a repeating twist. The presence of CSF does not
induce any morphological differences that are discernable with
the current method.
Aβ42 aggregation kinetics at constant CSF concentration.
When comparing different pools of CSF we noted a small dis-
crepancy in ﬁbrillation times depending on the pool used.
Therefore, when we next studied the aggregation kinetics starting
from a range of Aβ42 monomer concentrations (0.8–10 µM) at
constant concentration of CSF (15%, 32%, or 66%), two different
pools of CSF were used in a comparative fashion. The pools,
originating from two different clinics, were characterized in terms
of total protein concentration, ionic strength, and pH (Supple-
mentary Table 1) and used in separate experiments. The con-
centrations of CSF were chosen as described previously. All
samples contained 10 µM ThT, 20 mM HEPES/NaOH, 140 mM
NaCl, 1 mM CaCl2, pH 8.0. The experiment was repeated twice at
each CSF concentration with either triplicates or quadruplicates
of each Aβ42 concentration, meaning in total 6–8 kinetic curves
for each combination of Aβ42 and CSF concentration. The raw
data from one repeat at each CSF concentration—with a CSF pool
originating from Sahlgrenska Academy, Gothenburg University—
are shown in Fig. 4, and from the other repeats—with CSF from
Lund University—in Supplementary Figs. 6–8. The data in
Fig. 4d, e and Fig. 2a are color coded in the same way according
to CSF concentration for easy comparison. Clearly, in all cases the
aggregation at each monomer concentration is slower in the
presence of CSF compared to in pure buffer.
The half-time, t1/2, was extracted from each curve, plotted
versus Aβ42 concentration (Fig. 4d, e), and a power function was
ﬁtted to the resulting values (Eq. (1)). We ﬁnd that the scaling
exponent is γ=−0.8 in 15% CSF; γ=−0.9 in both 32% and 66%
CSF, although we note a deviation from the power function,
especially at 15% and 32% CSF. All of these γ values are lower
(more negative) than for Aβ42 in the HEPES buffer with
physiological salt, but similar to phosphate buffer at the same
ionic strength33 and higher (less negative) than the value found at
moderate ionic strength (I= 33 mM, γ=−1.3)32,33.
Kinetic analysis. To further study the aggregation mechanism of
Aβ42—speciﬁcally, whether the double nucleation mechanism
discovered in pure buffer (Fig. 5) exists also in CSF—a range of
kinetic models were globally ﬁtted to each data set using the
Amyloﬁt interface45 to ﬁnd the minimal model that can repro-
duce all data. As shown in the Fig. 6a, c, e, g, a model that
includes only primary nucleation and elongation cannot ﬁt any of
the data obtained in the presence of 0%, 15%, 32%, or 66% CSF,
requiring the presence of an additional step, such as secondary
nucleation, in all cases.
First, we analyzed the aggregation kinetics data as a function of
Aβ42 monomer concentration in 20 mM HEPES/NaOH, 140 mM
NaCl, 1 mM CaCl2, pH 8.0. The low dependence on monomer
concentration indicates that the reaction order of the secondary
process is very low. We therefore chose a model which includes
primary nucleation, elongation, and a secondary nucleation
process that is explicitly treated as a multi-step mechanism and
can thus saturate and lose its monomer concentration-
dependence at high monomer concentrations36. This model was
then used to successfully ﬁt all other CSF concentrations as well;
the parameters extracted from this model can be found in
Supplementary Table 2 (misﬁts to an alternative model can be
found in Supplementary Fig. 9).
In all of 15%, 32%, and 66% CSF (Fig. 6b, d, h), the aggregation
is retarded relative to buffer over the entire monomer
concentration range. The delay is reﬂected in an increase in lag
time and all curves have very steep transitions. For the data at
15% CSF, good ﬁts can again be achieved with the same model as
in buffer, a mechanism including a multi-step secondary
nucleation process. In 15% CSF the saturation of secondary
nucleation occurs over the range of concentrations sampled, as
indicated by the positive curvature in the half time plots. The
aggregation of Aβ42 in high ionic strength phosphate buffer also
follows this mechanism33. In 32% and 66% CSF the data again
display a low monomer dependence as for the buffer case. The ﬁts
reﬂect this; the saturation concentration for secondary nucleation
lies well below any of the sampled concentrations, meaning this
process is saturated at all concentrations studied. For all three
CSF concentrations, the model including primary nucleation,
elongation, and fragmentation also gave improved ﬁts compared
to models including only primary nucleation and elongation;
however, when investigating the mean residual error (MRE) as
calculated by Amyloﬁt, we found that a model including
fragmentation instead of multi-step secondary nucleation had a
higher MRE for all CSF concentrations, namely 165% increase for
0%
a
b
c
15%
66%
L4
Fig. 3 Cryo-EM images. Cryo-EM images of the ﬁnal aggregates formed
in solutions with a total monomer concentration of 10 µM and a 0%, b 15%,
or c 66% CSF. The hexagonal ﬁgure represents the CSF pool used. Scale
bar= 200 nm
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15% CSF over 24,188 data points; 3.2% increase for 32% CSF over
36,988 data points; and 6.7% increase for 66% CSF over 36,096
data points (Supplementary Fig. 10). Given this observation,
along with the identiﬁcation of multi-step secondary nucleation
as the main mechanism in phosphate buffer at the same ionic
strength33, we conclude multi-step secondary nucleation to be the
more likely mechanism in CSF as well.
The key ﬁnding of the kinetic analysis, which is consistent
across all CSF concentrations, is thus a failure to ﬁt the data
unless a secondary nucleation pathway is included in the model.
Indeed, models that lack this pathway fail to reproduce the data
(Fig. 6a, c, e, f). This implies that the secondary nucleation
pathway, discovered for Aβ42 in pure buffer system32, is a
dominant microscopic mechanism for the generation of new
aggregates also in CSF.
Seeding experiments. To further verify the presence of a sec-
ondary pathway, the effect of preformed ﬁbrils on aggregation
time was investigated (Fig. 7). Seed ﬁbrils were prepared from 3
70,000 50,000
40,000
30,000
20,000
10,000
0
15%a
d e
b c32% 66%
G1 G1 G1
10
8.0
6.3
5.0
4.0
3.2
2.5
2.0
1.6
1.3
1.0
0.8
10
8.0
6.3
5.0
4.0
3.2
2.5
2.0
1.6
1.3
1.0
0.8
10
8.0
6.3
5.0
4.0
3.2
2.5
2.0
1.6
1.3
1.0
0.8
Th
T 
flu
or
es
ce
nc
e 
(a.
u.)
t 1/
2 
(h)
lo
g(t
1/
2)
60,000
50,000
40,000
30,000
20,000
10,000
0
60,000
50,000
40,000
30,000
20,000
10,000
0
0
7 10
1
0.1
6
5
4
3
2
1
0
0 2 4 6
[Aβ42] (μM) log[Aβ42]
8 10 1 10
0%
15%
32%
66%
1 2 3
Time (h)
4 5 6 0 1 2 3 4
Time (h)
5 6 7 0 1 2 3 4
Time (h)
5 6 7 8
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nc Rate = k2 [M] [m]n2 Rate = 2 k+ [P] [m]
Fig. 5 The double nucleation mechanism. The double nucleation mechanism discovered for Aβ42 in a phosphate buffer32. Primary nucleation is a reaction
starting from monomers in solution and in the kinetic description used here leads directly to growth competent species. The rate at which this process
yields new ﬁbrils, [P], is given by kn[m]nc, where [m] is the monomer concentration, [P] is the ﬁbril concentration in ﬁbril units and nc is the reaction order,
which constitutes a lower bound for the number of monomers in the nucleus. Secondary nucleation is a reaction whereby monomers from solution react on
the ﬁbril surface and in the kinetic description used here leads directly to growth competent species in solution. The rate at which this process yields new
ﬁbrils, [P], is given by k2[M][m]n2, where [m] is the monomer concentration, [M] is the ﬁbril concentration in monomer units, and n2 is the reaction order,
which constitutes a lower bound for the number of monomers in the nucleus. Elongation is a reaction whereby monomers add to the ﬁbril ends to extend
the ﬁbril by one monomer unit. The rate at which this process yields new ﬁbril mass, [M], is given by 2k+[P][m], where [m] is the monomer concentration
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µM monomeric Aβ42 solutions in 20 mM HEPES/NaOH, 140
mM NaCl, 1 mM CaCl2, 10 µM ThT, pH 8.0 with 0% and 66%
CSF, respectively. The seed ﬁbrils were then added to 3 µM
monomeric Aβ42 solutions in the same solution conditions to
ﬁnal seed concentrations of 30%, 10%, 3%, 1%, and 0% of the
monomer concentration in monomer equivalents. In both con-
ditions the addition of seeds shortens the lag phase in a non-
linear fashion and even the lowest seed concentration (1%) leads
to a considerable shortening of the lag phase, as shown also in the
t1/2-plots. Even at the highest seed concentration the aggregation
does not start immediately creating an apparent lag phase,
which may be partly due to the time it takes for the solution to
reach 37 °C.
We attempted to make ﬁts to the seeded data using models and
rate constants that were consistent with the results from the
unseeded experiments (Supplementary Fig. 11). Again it was clear
that a model including only nucleation and elongation could not
reproduce the data, the inclusion of secondary processes is
necessary, especially to capture the strong effects of low seed
concentrations. Only the model relying on secondary nucleation
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gave ﬁts that could reproduce both the shape of the curves and
the dependence on seed concentration. However, the ﬁts to the
seeded data were found to be signiﬁcantly worse than ﬁts to the
unseeded data, which may be due to components from CSF
interacting with mature ﬁbrils and altering their seeding abilities.
Discussion
The mechanism of Aβ aggregation in vivo remains elusive,
although kinetic studies in pure buffer provide clues as to which
microscopic steps might be present. In this study, we have
expanded these studies towards an in vivo-like situation using
human CSF spiked with recombinant human Aβ42 peptide.
Based on the results we can conclude the following:
Aβ42 forms ﬁbrils in CSF. Although the presence of CSF
certainly delays ﬁbril formation49–51, Aβ42 is found to form ThT-
positive aggregates at all CSF concentrations studied (up to 90%).
The cryo-EM images clearly show that ﬁbrils are formed in
samples containing 15% or 66% CSF, with a morphology
resembling those formed in buffer at similar ionic strength33.
Curiously, in several ﬁelds of the images, small particles seem to
be associated with the surface of the ﬁbrils and these features are
more prevalent in images taken at the higher concentration of
CSF. This is interesting in light of the identiﬁcation of HDL-like
components in the retarding fraction of size-separated CSF49.
However, the cryo-EM images alone do not allow for identiﬁca-
tion of the bound species and further investigation would be
required.
Reproducible data amenable to kinetic analysis can be obtained
in CSF. Kinetic analysis requires high quality, reproducible data.
The addition of a complex biological ﬂuid such as CSF could
potentially interfere with the aggregation kinetics in a number of
ways, and we ask what level of reproducibility can be achieved
between and within CSF pools. Most notably, any body ﬂuid will
contain thousands of high and low Mw proteins or other com-
ponents with varying inﬂuence on the aggregation process. The
kinetic data will report on a net effect of all these components and
a variation in the composition of the CSF may modulate this net
effect. Five CSF pools from healthy donors collected at two dif-
ferent clinics were used in the current study. The data in Figs. 2, 3,
7, and Supplementary Figs. 2–9 were obtained using four CSF
pools from Lund University Hospital, whereas data obtained
using one CSF pool from Sahlgrenska Academy, Gothenburg
University are shown in Figs. 1, 4, and 6. Although some minor
differences in curve shape can be detected when comparing the
data at 66% CSF from Gothenburg with the data at 66% CSF from
Lund, the overall appearance is very similar and the observed t1/2
versus Aβ42 concentrations superimpose closely (Fig. 4c, d,
Supplementary Fig. 8). The slight variation between kinetic
curves, as well as the variation seen between pools in terms of CSF
concentration dependence at ﬁxed Aβ42 concentration, is most
likely due to variations between the individuals donating the CSF
(a comparison of some general properties between two pools of
CSF is summarized in Supplementary Table 1). Still, the repro-
ducibility between replicates of the same Aβ42 concentration
found at 15% as well as 32% and 66% CSF is remarkably high.
Some discrepancy between the t1/2 times from Fig. 2 and Figs. 1
and 4 can be noted, which could due to different CSF pools being
used; however, the macroscopic behavior—with retardation at
higher CSF concentration as well as saturation of the effect—
remains the same over all CSF pools used. In addition, there are
potential practical complications associated with the use of bio-
logical ﬂuids, including difﬁculties of accurately dispensing a
viscous ﬂuid, loss of ﬂuorescent signal due to interfering
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chromophores or spurious signals from unknown aggregating
proteins in solution. The ﬁrst two issue do not pertain to CSF
which is a transparent, Newtonian ﬂuid with a viscosity close to
that of water52. We cannot rule out that CSF itself might contain
proteins that aggregate and bind ThT, or co-aggregate with the
added Aβ42, as we do see a slight variation in the amplitude of
the ﬂuorescence change in some of the CSF pools. However, when
CSF was incubated with ThT without added Aβ42, some increase
of ThT ﬂuorescence was observed within 25 h (Supplementary
Fig. 3a), but very much lower than the change in the presence of
Aβ42; therefore, this does not interfere with reproducibility, nor
hamper our analysis.
The models of aggregation of pure protein are able to repro-
duce the data in pure buffer (Fig. 6a). Although they perform less
well in the presence of CSF, with some deviations in curve shape,
the overall behavior and concentration dependence is ﬁtted sur-
prisingly well. This observation indicates that the presence of the
wide range of biological compounds contained in CSF can be
approximated simply as perturbations to the rate constants of
aggregation, leaving the basic mechanism unchanged. The
deviation in curve shape could possibly be caused by interactions
in CSF between Aβ42 and some species, with the dissociation of
any formed complexes being rate limiting and affecting the
reaction proﬁle; however, further studies would be necessary for
full disclosure of the possibilities behind the deviations. Still, the
present ﬁndings show that it is feasible to study the aggregation
kinetics of Aβ peptides in CSF, with high reproducibility between
replicates of considerable value for drug discovery programs.
Indeed, a recent study47 used this opportunity to validate that
small molecules, discovered to retard speciﬁc microscopic steps in
the Aβ42 aggregation process in buffer, caused prominent
retardation also in CSF as a representative of a more natural
environment in addition to a pure buffer system.
The autocatalytic nature of the process, including a double
nucleation mechanism originally found in pure buffer, is pre-
valent in CSF. In HEPES buffer with physiological salt (20 mM
HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0), good global
ﬁts to the data could be achieved by a double nucleation model
including primary nucleation of monomers in solution and multi-
step secondary nucleation of monomers on ﬁbril surface (Fig. 6b).
The same mechanism was identiﬁed in a recent study in phos-
phate buffer at the same ionic strength (4 mM sodium phosphate,
0.04 mM EDTA, 150 mM NaCl, pH 8.033) with the main differ-
ence being that both primary and secondary nucleation seemed to
follow a reaction order of two in the latter case. The effects of
adding premade ﬁbrils to the reaction mixture, i.e. shortening of
the lag phase in a manner that can only be explained by the
presence of secondary processes, further supporting this.
The aggregation mechanism can be described in the same
manner as in pure buffer, but the rate constants for the individual
microscopic steps are affected by CSF. Having found a unifying
model that can describe all the data in buffer and at both CSF
concentrations tested, it is interesting to analyze how the para-
meters differ between the conditions. The most consistent effect
of adding CSF is a decrease of the secondary nucleation rate. This
reduction might be connected to the small objects observed along
some ﬁbrils in the cryo-EM images that could possibly be a
component of CSF binding to the surface of the ﬁbrils and thus
reducing the rate of secondary nucleation on this surface. Future
work might examine if there are differences in Aβ aggregation
characteristics in CSF obtained from individuals with and without
biomarker evidence of cerebral β-amyloidosis.
To summarize, we found that ﬁbrils are formed in the presence
of CSF and are of similar morphology as those formed in buffer.
Monitoring of ThT ﬂuorescence yielded reproducible kinetic data
of aggregation in CSF, which could be analyzed by global ﬁtting of
the same rate laws that apply to the aggregation in pure buffer.
This highlights that the presence of CSF can be approximated as a
perturbation to the rate constants of aggregation in pure buffer
and, most importantly, that the autocatalytic nature of the pro-
cess, including a double nucleation mechanism, is present also in
CSF. The main retarding effect of CSF on the aggregation of
Aβ42 stems from a reduction of the rate of secondary nucleation.
The decrease in secondary nucleation rate suggests that an inhi-
bitor of secondary nucleation may be responsible for the
retardation.
Our ﬁndings illustrate how aggregation kinetics in pure buffer
can identify the microscopic steps in the aggregation reaction and
then be used to translate these ﬁndings to the in vivo situation by
repeating the aggregation reaction in increasing concentrations of
bodily ﬂuids. By identifying which processes are most affected
this approach points towards possible mechanisms of action and
can quantify the effect on different steps and under different
conditions. The ability to study aggregation at a quantitative,
mechanistic level in bodily ﬂuids is key for investigating the
differences in CSF obtained from individuals with and without
AD and may help determine the presence of disease enhancing or
retarding factors in different individuals.
Methods
Validation of automated pipetting by robot. All dilutions of Aβ monomers in
this work were performed by an in-house constructed automated dispenser robot.
The accuracy and precision of this robot was validated by creating dilution series of
a ﬂuorescent dye. Buffer A was created by dissolving pyranine dye (8-hydro-
xypyrene-1,3,6-trysulfonic acid trisodium salt, Invitrogen) to a concentration of 2
µM in 50 mM bicine–HCl, pH 9.0. Buffer B consisted of pure 50 mM bicine–HCl,
pH 9.0. The pipetting robot was used to dispense 24 different combinations of the
two buffers, ranging from 100 µL A+ 0 µL B to 0 µL A+ 100 µL B into separate
wells in a 96-well plate. Each set contained four replicates of every concentration
and three independent sets were made. The ﬂuorescence intensities of the resulting
dye solutions were recorded at 510 nm with an excitation light at 450 nm in a
CLARIOstar plate reader (BMG Labtech).
CSF pools. De-identiﬁed pooled CSF from healthy donors was used in all
experiments. Five different pools were used: one from the Clinical Neurochemistry
Laboratory, Sahlgrenska University Hospital, Gothenburg, and four from Lund
University Hospital. Each pool was frozen at −80 °C as multiple identical 1 mL
aliquots. Upon thawing, the CSF sample was supplemented with 20 mM HEPES
from a 30× concentrated stock to adjust pH to 8.0. Assuming literature values of
salt concentrations, the CSF stock was then assumed to contain 97% CSF, 20 mM
HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0. The CSF pool was prepared
from de-identiﬁed left-over aliquots from clinical routine analyses, following a
procedure approved by the Ethics Committee at University of Gothenburg (EPN
140811).
Characterization of CSF pools. A comparison between one pool of CSF from the
Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital and one pool
from Lund University Hospital was made, in terms of pH, conductivity (ionic
strength), and overall protein content. The pH was measured using a Mettler
Toledo MP225 pH-meter; the conductivity was measured using a CONSORT C830
pH/mV/Conductivity/°C-meter; ﬁnally, the total protein content was determined
using the Bradford assay53, with human IgG as standard.
Cloning and expression of Aβ peptides. A synthetic gene with E. coli optimized
codons for Aβ(M1-42) was produced by PCR from overlapping oligonucleotides
and cloned into PetSac, a derivative of Pet3a plasmid54. The peptides were
expressed in E. coli strain BL21 DE3 PLyS star (Invitrogen) in LB medium with 50
mg L−1 ampicillin and 30 mg L−1 chloramphenicol. Well-isolated small colonies
from bacteria freshly transformed with vector were used to inoculate 50 mL
overnight cultures grown in 250 mL bafﬂed ﬂasks at 37 °C with 125 rpm shaking.
These were diluted 1:100 into 500 mL day cultures grown in 2500 mL bafﬂed ﬂasks
at 37 °C with 125 rpm shaking. 0.4 mM IPTG was added at OD 0.6–1.0 and the
cells were harvested after another 3.5–4 h by centrifugation for 10 min at 6000 × g.
Puriﬁcation of Aβ peptides. Cell pellet from 2 L culture was sonicated in 40 mL
10 mM Tris/HCl, 1 mM EDTA, pH 8.5 (buffer A) using a sonicator tip (half horne,
50% duty cycle, maximum output, 30–90 s). This step was performed in a glass
beaker surrounded by an ice–water slurry. Inclusion bodies were isolated by cen-
trifugation at 4 °C, 15,000 × g for 10 min. Two more rounds of sonication and
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centrifugation were performed. The inclusion bodies were dissolved in 40 mL 8M
urea in buffer A, and diluted four-fold in buffer A. 20 mL DEAE cellulose
(Whatman DE23, equilibrated in buffer A with 2 M urea) was added and the slurry
was left on ice for 30 min (with stirring now and then using a glass rod). The
solution was removed and the resin was washed with buffer A in a Büchner funnel
on a vacuum ﬂask, followed by two washes with 30 mL buffer A with 25 mM NaCl
and elution in buffer A with 50 mM NaCl, 6× 30 mL or 125 mM NaCl 3× 30 mL.
The ion-exchange puriﬁcation was performed in batch mode to avoid concentra-
tion of the peptide on the resin. The eluted fractions were examined using agarose
gel electrophoresis and SDS–PAGE. Fractions containing Aβ42 were pooled, lyo-
phylized, dissolved in 6M GuHCL and again puriﬁed by SEC on a 2.6 × 60 cm
Superdex 75 column in 20 mM NaP, 0.2 mM EDTA, pH 8.5. The eluted fractions
were examined using UV absorbance and SDS–PAGE. Pure fractions were pooled,
aliquoted, lyophylized, and stored at −20 °C.
Chemicals. All chemicals were of analytical grade. Buffers were extensively
degassed.
Preparation of samples for kinetics experiments. Aliquots of puriﬁed Aβ42 were
dissolved in 6M GuHCl, and monomer isolated by gel ﬁltration on a Superdex 75
column in 20 mM HEPES/NaOH, pH 8.0. The gel ﬁltration steps remove traces of
pre-existent aggregates and exchanges the buffer to the one used in the ﬁbril
formation experiments. The peptide concentration was determined from the
absorbance of the integrated peak area using ε280= 1400 Lmol−1cm−1 as cali-
brated using quantitative amino acid analysis. The concentration determined by
this method is correct within ± 20% or better. The monomer generated in this way
was diluted with buffer to 10 µM and supplemented with 10 μM thioﬂavinT (ThT,
Calbiochem) from a 2 mM stock (in water, ﬁltrated through 0.2 µm ﬁlter). All
samples were prepared in low-binding Eppendorf tubes (Axygen, California, USA)
on ice using careful pipetting to avoid introduction of air bubbles. The monomer
sample was supplemented with 140 mM NaCl and 1 mM CaCl2. The CSF con-
centration series was prepared from a monomer stock, buffer, and CSF to yield
samples with none or 1.2–80% CSF. The Aβ42 concentration series were prepared
from samples with CSF concentrations of either 0%, 15%, 32%, or 66% along with
buffer, and Aβ42 to yield samples with 10–0.8 µM Aβ42. Each sample was pipetted
into three or four wells of a 96-well half-area plate of black polystyrene with a clear
bottom and PEG coating (Corning 3881, Massachusetts, USA), 100 μL per well,
using the pipetting robot.
Kinetic assays. Assays were initiated by placing the 96-well plate at 37 °C under
quiescent conditions in a plate reader (Fluostar Omega or Fluostar Optima
BMGLabtech, Offenburg, Germany). The ThT ﬂuorescence was measured through
the bottom of the plate every 60 s with a 440 nm excitation ﬁlter and a 480 nm
emission ﬁlter.
Seeded assays. The seed ﬁbrils were prepared from 3 µM monomer solutions (in
20 mM HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0, 10 µM ThT, as above)
supplemented with 0% or 66% CSF and incubated at 37 °C under quiescent con-
ditions in a plate reader until the ThT ﬂuorescence reached a plateau value. The
seed ﬁbrils were added to monomer solutions (in 20 mM HEPES/NaOH, 140 mM
NaCl, 1 mM CaCl2, pH 8.0, 10 µM ThT, as above). The ﬁnal seed concentrations
were 30%, 10%, 3%, 1%, and 0% of the monomer concentration in monomer
equivalents. Each mixture was then pipetted into three different wells in a 96-
well plate.
Cryo-EM. Samples containing 10 µM Aβ42 in either 15% or 66% CSF, 10 µM ThT,
20 mM HEPES/NaOH, 140 mM NaCl, 1 mM CaCl2, pH 8.0 were prepared using
the ThT ﬂuorescence assay as described above. After reaching the plateau, the
samples were put on ice. Specimens for electron microscopy were prepared in a
controlled environment vitriﬁcation system (CEVS) to ensure stable temperature
and to avoid loss of solution during sample preparation. The specimens were
prepared as thin liquid ﬁlms, <300 nm thick, on lacey carbon-ﬁlmed copper grids
and plunged into liquid ethane at −180 °C. This leads to vitriﬁed specimens,
avoiding component segmentation and rearrangement, and the formation of water
crystals, thereby preserving original microstructures. The vitriﬁed specimens were
stored under liquid nitrogen until measured. A Fischione Model 2550 cryo transfer
tomography holder was used to transfer the specimen into the electron microscope,
JEM 2200FS, equipped with an in-column energy ﬁlter (Omega ﬁlter), which allows
zero-loss imaging. The acceleration voltage was 200 kV and zero-loss images were
recorded digitally with a TVIPS F416 camera using SerialEM under low dose
conditions with a 30 eV energy selecting slit in place.
Kinetic analysis. Determination of the scaling factor was done by ﬁtting the
described equation to the t1/2 plots. This was done by using the power function in
KaleidaGraph, ver. 4.1.1.
Global analysis of Aβ42 aggregation kinetics to extract the rate constants for
primary nucleation, secondary nucleation, and elongation was performed using the
online Amyloﬁt platform45. At each condition (buffer only, buffer with 15% CSF,
buffer with 32% CSF, or buffer with 66% CSF) ﬁts were made to the data using the
following integrated rate law for the normalized aggregate concentration
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In these relations, [m]0 is the initial monomer concentration, [P]0 is aggregate
number at the start of the reaction, [P]∞ is the aggregate number at equilibrium,
that is, after reaction completion, [M]0 is the mass concentration of ﬁbrils at the
start of the reaction and [M]∞ is the mass concentration of ﬁbrils at equilibrium. kn,
k2, k+ are the rate constants for primary nucleation, secondary nucleation, and
elongation, respectively. KM is the saturation constant for secondary nucleation and
nc and n2 are the monomer scalings of primary and secondary nucleations,
respectively. The values nc= 0.00001, and n2= 2 were used for ﬁtting of the
kinetics in buffer, and the values nc= 3 and n2= 2 for the ﬁtting of all aggregation
kinetics in the presence of CSF.
The effective rate of formation of new aggregates through secondary nucleation
at a given concentration was calculated using the following relation:
dP2
dt
¼ k2 M½ 
mn2
1þ mn2KM
ð8Þ
Statistics and reproducibility. In this work each experiment consists of a dilution
series created by the pipetting robot by dispensing different volumes of stock
solution containing Aβ42 and/or CSF and buffer into a 96-well plate to achieve the
desired concentrations. Replicates within one experiment are created by dispensing
the same volumes in several consecutive wells. Independent repeats of experiments
were made always made using new stock solutions, when new CSF pools were used
this has been indicated. All error bars are showing the standard deviation of such
replicates within one experiment. Separate repeats of the same experiments are
always shown in separate ﬁgures or panels.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
Raw data are shown in Figs. 1–4 and Supplementary Figs. 1–4, 6–8. Normalized data are
shown in Figs. 6, 7 and Supplementary Figs. 5, 9, and 11. The data underlying Fig. 1 are
shown in Supplementary Data 1. The data underlying Fig. 2 are shown in Supplementary
Data 2. The data underlying Fig. 4 are shown in Supplementary Data 3. The data
underlying Fig. 6 are shown in Supplementary Data 4. The data underlying Fig. 7 are
shown in Supplementary Data 5. All other data will be made available upon request.
Code availability
The software used to analyze the data can be accessed at http://www.amyloﬁt.ch.cam.ac.uk.
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